Trials / Active Not Recruiting
Active Not RecruitingNCT05889143
A Study to Evaluate the Efficacy and Safety of CREZET Tablet
A Prospective, Non-Intervention, Multi-Center Observational Study to Evaluate the Efficacy and Safety of CREZET Tablet in Patients With Dyslipidemia
- Status
- Active Not Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 15,000 (estimated)
- Sponsor
- Daewoong Pharmaceutical Co. LTD. · Industry
- Sex
- All
- Age
- 19 Years
- Healthy volunteers
- Not accepted
Summary
This observation study is to evaluate blood lipid-lowering effects and liver/renal safety, changes in HbA1c and FPG in patients with dyslipidemia who administered CREZET tablets for 24 weeks.
Detailed description
A subject who is diagnosed with dyslipidemia and scheduled to administer CREZET tablets, will be enrolled in this study based on the doctor's medical decision. The CREZET Tablet will be administered for 24 weeks, and the data including demographic information, body measurement, vital signs and etc will be collected during the study period. The data collection point is as follows. 1. Visit 1 (baseline, day 0) 2. Visit 2 (at 12 weeks) 3. Visit 3 (at 24 weeks)
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ezetimibe/Rosuvastatin | Patient treated with Crezet Tablet |
Timeline
- Start date
- 2023-05-24
- Primary completion
- 2024-12-31
- Completion
- 2026-03-01
- First posted
- 2023-06-05
- Last updated
- 2025-08-24
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT05889143. Inclusion in this directory is not an endorsement.